NeoGenomics, Inc. (NEO) AI Stock Analysis

NeoGenomics operates an extensive network of laboratories dedicated to cancer-focused testing across the United States, Europe, and Asia. The company is structured into Clinical Services and Pharma Services segments, providing testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. In its Clinical Services segment, NeoGenomics offers cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry with digital imaging, molecular testing of DNA and RNA, and morphologic analysis. Its Pharma Services segment supports pharmaceutical clients with comprehensive oncology testing from discovery through commercialization. Headquartered in Fort Myers, Florida, NeoGenomics maintains strategic alliances with entities such as Inivata Limited.

Revenue grew from $484.3M in FY2021 to $727.3M in FY2025, supported by a 5-year CAGR of 10.4%. Net income remained negative across this period, moving from -$8.3M in FY2021 to -$108.0M in FY2025, alongside an operating margin of -9.1%. Gross margin was 38.8% in FY2025 compared to 38.6% in FY2021. For the trailing twelve months, revenue reached $766.3M with an operating margin of -4.8% and an EPS of -$0.39. In the latest quarter ending June 30, 2026, quarterly revenue increased 11.2% year-over-year while quarterly earnings expanded by 130.6%.

As of June 30, 2026, NeoGenomics held $145.5M in cash and short-term investments against $448.4M in total debt, resulting in net debt of $302.8M. Total assets stood at $1.35B and shareholders' equity was $785.7M, yielding a debt-to-equity ratio of 0.57 and a current ratio of 3.60. Operating cash flow reached $5.2M in FY2025, while capital expenditures of $27.0M led to free cash flow of -$21.8M. The company's share count increased 6.3% over five years.

NeoGenomics trades at a forward P/E of 222.2x and an EV to EBITDA of 197.3x, compared to medians of 17.3x and 12.0x for its US-listed Healthcare peers. Its price-to-sales multiple is 2.8x, below the peer group median of 4.1x. The company has an enterprise value of $2.66B and a market cap of $2.14B. Over the past year, the stock returned 62.0%, outperforming the S&P 500 return of 16.8%, although its 5-year return of -61.6% lags the index gain of 83.0%.

Wall Street coverage includes 7 Strong Buy, 2 Buy, and 3 Hold ratings, with 0 Sell ratings. The mean price target is $21.85, representing a 31.2% premium over the last close of $16.65 on October 16, 2026. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $805.2M and EPS of $0.19. The company beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is October 28, 2026.

This page is an AI-written research summary of NeoGenomics, Inc. (NEO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NEO income statement, NEO balance sheet, NEO key metrics, NEO analyst forecast, NEO chart. See the NEO stock overview for the latest quote and news.